DBV Technologies Announces Resignation of Board Member
DBV Technologies (NASDAQ: DBVT) announced the immediate resignation of Daniel Soland from its Board of Directors. Soland, who joined the board in 2015, served on the Compensation Committee and contributed his expertise to the company's development of the VIASKIN® Peanut patch for peanut allergic children.
The Board will continue to operate with 9 remaining members while the Nomination and Governance Committee evaluates the timing and process for appointing a new member, subject to shareholder ratification at the next Annual General Meeting.
DBV Technologies (NASDAQ: DBVT) ha annunciato le immediate dimissioni di Daniel Soland dal Consiglio di Amministrazione. Soland, entrato nel consiglio nel 2015, è stato membro del Compensation Committee e ha contribuito con la sua esperienza allo sviluppo della patch VIASKIN® Peanut per i bambini allergici alle arachidi.
Il Consiglio continuerà a operare con 9 membri rimanenti, mentre il Comitato per le Nomination e la Governance valuterà i tempi e la procedura per nominare un nuovo membro, soggetto all'approvazione degli azionisti nella prossima Assemblea Generale Annuale.
DBV Technologies (NASDAQ: DBVT) anunció la renuncia inmediata de Daniel Soland a su Junta Directiva. Soland, que se incorporó a la junta en 2015, formó parte del Comité de Compensación y aportó su experiencia al desarrollo de la patch VIASKIN® Peanut para niños alérgicos al maní.
La Junta continuará funcionando con 9 miembros restantes, mientras el Comité de Nombramientos y Gobernanza evalúa el momento y el proceso para designar a un nuevo miembro, sujeto a la ratificación por parte de los accionistas en la próxima Junta General Anual.
DBV Technologies (NASDAQ: DBVT)는 다니엘 솔란드가 이사회에서 즉시 사임했다고 발표했습니다. 2015년 이사회에 합류한 솔란드는 보상위원회에서 활동했고 VIASKIN® Peanut patch의 개발에 그의 전문 지식을 기여했습니다.
이사회는 9명의 잔여 이사로 계속 운영되며, 지명 및 거버넌스 위원회가 새 이사 임명 시기와 절차를 평가하고 다음 연례 일반 주주총회의 주주 확인에 따라 결정합니다.
DBV Technologies (NASDAQ: DBVT) a annoncé la démission immédiate de Daniel Soland de son conseil d'administration. Soland, qui a rejoint le conseil en 2015, faisait partie du Comité de rémunération et a apporté son expertise au développement de la patch VIASKIN® Peanut pour les enfants allergiques aux arachides.
Le conseil continuera de fonctionner avec 9 membres restants, tandis que le Comité de nomination et de gouvernance évalue le calendrier et la procédure pour nommer un nouveau membre, sous réserve de l'approbation des actionnaires lors de la prochaine Assemblée générale annuelle.
DBV Technologies (NASDAQ: DBVT) gab den sofortigen Rücktritt von Daniel Soland aus dem Verwaltungsrat bekannt. Soland, der 2015 in das Gremium eingetreten war, gehörte dem Vergütungsausschuss an und trug mit seiner Expertise zur Entwicklung der VIASKIN® Peanut patch für erdnussallergische Kinder bei.
Der Vorstand wird mit 9 verbleibenden Mitgliedern weiterarbeiten, während der Nominierungs- und Governance-Ausschuss das Timing und den Prozess für die Ernennung eines neuen Mitglieds prüft, vorbehaltlich der Zustimmung der Aktionäre auf der nächsten Hauptversammlung.
أعلنت DBV Technologies (السهم: DBVT) استقالة فورية من DANIEL SOLAND من مجلس إدارتها. Solver Soland، الذي انضم إلى المجلس في 2015، كان عضواً في لجنة التعويضات وقدم خبرته في تطوير VIASKIN® Peanut patch للأطفال المصابين بحساسية الفول السوداني.
سيستمر المجلس في العمل بـ 9 أعضاء متبقين بينما تقيّم لجنة الترشيحات والحوكمة توقيت وإجراءات تعيين عضو جديد، رهناً بموافقة المساهمين في الاجتماع العام السنوي القادم.
DBV Technologies (NASDAQ: DBVT) 公告董事会立即辞去 Daniel Soland 的职务。Soland 自2015年加入董事会，曾担任薪酬委员会成员，并为公司开发用于花生过敏儿童的 VIASKIN® Peanut patch 提供了专业意见。
董事会将以 9 名剩余成员继续运作，而提名与治理委员会将评估任命新成员的时机和程序，并在下一次年度股东大会上提交股东批准。
- None.
- None.
Châtillon, France, September 18, 2025
DBV Technologies Announces Resignation of Board Member
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the “Board”), effective immediately.
“On behalf of the Board, DBV’s management team and shareholders, I thank Daniel for his commitment to the Company,” said Michel de Rosen, Chairman of the Board. “Since joining the Board in 2015, Daniel’s experience, insights and expertise have been invaluable to the Board and its Compensation Committee. We wish him continued success in his future endeavors.”
“It has been a pleasure to serve on the Board and work with the DBV management team,” said Daniel Soland. “I look forward to watching the Company continue to advance the VIASKIN® Peanut patch and potentially bring a much needed treatment option to peanut allergic children and their families if approved.”
The Board of Directors will continue to operate with its 9 remaining members and will evaluate with its Nomination and Governance Committee the appropriate timing and process for the provisional appointment of a new member to fill Mr. Soland’s vacancy, subject to ratification by the Company’s shareholders at the next Annual General Meeting.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
Why did Daniel Soland resign from DBV Technologies (DBVT) Board of Directors?
How long did Daniel Soland serve on DBV Technologies' Board?
How many members remain on DBV Technologies' Board after Soland's resignation?
What is DBV Technologies' main product in development?
